Copyright
©The Author(s) 2018.
World J Gastroenterol. Feb 14, 2018; 24(6): 725-736
Published online Feb 14, 2018. doi: 10.3748/wjg.v24.i6.725
Published online Feb 14, 2018. doi: 10.3748/wjg.v24.i6.725
Factors | Univariate analysis | Multivariate analysis | ||||
HR | 95%CI | P value | HR | 95%CI | P value | |
Sex (female vs male) | 1.14 | 0.72-1.81 | 0.57 | 1.39 | 0.78-2.47 | 0.27 |
Age (yr) | 0.99 | 0.97-1.01 | 0.53 | 0.99 | 0.96-1.01 | 0.31 |
HBV genotype (B vs C)1 | 1.17 | 0.70-1.93 | 0.55 | 1.34 | 0.79-2.30 | 0.28 |
ALT (× ULN) | 1.00 | 0.96-1.04 | 0.94 | 0.99 | 0.94-1.04 | 0.65 |
HBV DNA (≤ 4 vs > 4 log IU/mL) | 1.33 | 0.73-2.40 | 0.35 | 0.63 | 0.19-2.07 | 0.45 |
HBsAg (< 2.4 vs ≥ 2.4 log IU/mL) | 3.95 | 2.19-7.12 | < 0.001 | 3.12 | 1.58-6.19 | 0.001 |
- Citation: Lin TC, Chiu YC, Chiu HC, Liu WC, Cheng PN, Chen CY, Chang TT, Wu IC. Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy. World J Gastroenterol 2018; 24(6): 725-736
- URL: https://www.wjgnet.com/1007-9327/full/v24/i6/725.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i6.725